Hypersensitivity reactions to anticoagulant drugs

Current Pharmaceutical Design

Volumn 14, Issue 27, 2008, Pages 2863-2873

  Scherer, Kathrin ^a   Tsakiris, Dimitrios A ^a   Bircher, Andreas J ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Acetylsalicylic acid; Allergy; Anticoagulants; Coumarins; Heparins; Hypersensitivity; Thienopyridins

Indexed keywords

15 HYDROXYICOSATETRAENOIC ACID; ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; COUMARIN DERIVATIVE; DESULFATOHIRUDIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; GALECTIN; GALECTIN 10; HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY; HIRUDIN DERIVATIVE; HIRULOG; INTERLEUKIN 5; INTERLEUKIN 8; LEPIRUDIN; PEPTIDOLEUKOTRIENE; PROTEIN C; PROTEIN S; THIENOPYRIDINE DERIVATIVE; THROMBOCYTE FACTOR 4; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG;

AGEUSIA; ALOPECIA; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ANTIGEN ANTIBODY REACTION; ARTHUS PHENOMENON; ASTHMA; BLEEDING; BLOOD TOXICITY; CARDIOGENIC SHOCK; CARDIOPULMONARY INSUFFICIENCY; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CHRONIC SINUSITIS; CONJUNCTIVITIS; CYTOKINE RELEASE; CYTOPENIA; DELAYED HYPERSENSITIVITY; DESENSITIZATION; DRESS SYNDROME; DRUG CROSS REACTIVITY; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOLERABILITY; EOSINOPHIL; ERYTHEMA; FACE EDEMA; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERCOAGULABILITY; HYPEREOSINOPHILIA; HYPOTENSION; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNE RESPONSE; KIDNEY DISEASE; LIPODYSTROPHY; LIVER DISEASE; LOW DRUG DOSE; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; NAUSEA; NEUTROPENIA; NONHUMAN; NOSE POLYP; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHOTOTOXICITY; PNEUMONIA; PRICK TEST; PRIORITY JOURNAL; PROVOCATION TEST; PRURITUS; REVIEW; RHINITIS; SERUM SICKNESS; SKIN NECROSIS; SKIN SENSITIZATION; SKIN TEST; STEVENS JOHNSON SYNDROME; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; TOXIC EPIDERMAL NECROLYSIS; URTICARIA;

ANIMALS; ANTICOAGULANTS; DRUG HYPERSENSITIVITY; HUMANS; SKIN TESTS;

EID: 65949084716     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786369768     Document Type: Review

References (109)

1. Bircher AJ, Harr T, Hohenstein L, Tsakiris DA. Hypersensitivity reactions to anticoagulant drugs: Diagnosis and management options. Allergy 2006; 61: 1432-40.
2. Hirsh J, O'Donnell M, Weitz JI. New anticoagulants. Blood 2005; 105: 453-63.
3. Jappe U. Allergy to heparins and anticoagulants with a similar pharmacological profile: An update. Blood Coagul Fibrinolysis 2006; 17: 605-13.
4. Veach SA, Franks AM, Allan MC. Severe anaphylactic reaction after repeated intermittent exposure to lepirudin. Pharmacotherapy 2007; 27: 760-5.
5. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 188S-203S.
6. Verstraete M. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs 1990; 40: 498-530.
7. Warkentin TE. An overview of the heparin-induced thrombocytopenia syndrome. Semin Thromb Hemost 2004; 30: 273-83.
8. Wutschert R, Piletta P, Bounameaux H. Adverse skin reactions to low molecular weight heparins: Frequency, management and prevention. Drug Saf 1999; 20: 515-25.
9. Jappe U, Gollnick H. Allergy to heparin, heparinoids, and recombinant hirudin. Diagnostic and therapeutic alternatives. Hautarzt 1999; 50: 406-11.
10. Bircher AJ. Allergische reaktionen vom spättyp auf heparine. Allergologie 1993; 16: 268-74.
11. Hohenstein E, Tsakiris D, Bircher AJ. Delayed-type hypersensitivity to the ultra-low-molecular-weight heparin fondaparinux. Contact Dermatitis 2004; 51: 149-51.
12. Ludwig RJ, Schindewolf M, Alban S, Kaufmann R, Lindhoff-Last E, Boehncke WH. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides. Thromb Haemost 2005; 94: 1265-9.
13. Bircher AJ, Flückiger R, Büchner S. Eczematous infiltrated plaques to subcutaneous heparin: A type IV allergic reaction. Br J Dermatol 1990; 123: 507-14.
14. Ludwig RJ, Schindewolf M, Utikal J, Lindhoff-Last E, Boehncke WH. Management of cutaneous type IV hypersensitivity reactions induced by heparin. Thromb Haemost 2006; 96: 611-7.
15. Häusermann P, Harr T, Bircher AJ. Baboon syndrome resulting from systemic drugs: Is there strife between SDRIFE and allergic contact dermatitis syndrome? Contact Dermatitis 2004; 51: 297-310.
16. Komericki P, Grims R, Kranke B, Aberer W. Acute generalized exanthematous pustulosis from dalteparin. J Am Acad Dermatol 2007; 57: 718-21.
17. Bircher AJ. The differential diagnosis of heparin-induced skin lesions. Br J Haematol 1993; 85: 837.
18. Jorg I, Fenyvesi T, Harenberg J. Anticoagulant-related skin reactions. Expert Opin Drug Saf 2002; 1: 287-94.
19. Harenberg J, Hoffmann U, Huhle G, Winkler M, Bayerl C. Cutaneous reactions to anticoagulants. Recognition and management. Am J Clin Dermatol 2001; 2: 69-75.
20. Bottio T, Pittarello G, Bonato R, Fagiolo U, Gerosa G. Life-threatening anaphylactic shock caused by porcine heparin intravenous infusion during mitral valve repair. J Thorac Cardiovasc Surg 2003; 126: 1194-5.
21. Harr T, Scherer K, Tsakiris D, Bircher AJ. Immediate type hypersensitivity to several low molecular weight heparins and tolerance of unfractioned heparin and fondaparinux. Allergy 2006; 61(6): 787-8
22. Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008; 358: 2457-67.
23. Giustolisi R, Guglielmo P, di Raimondo F, Cacciola E, Stagno F. Hypereosinophilia and subcutaneous heparin. Lancet 1993; 342: 1371.
24. Bircher AJ, Itin P, Büchner S. Skin lesions, hypereosinophilia, and subcutaneous heparin. Lancet 1994; 343: 861.
25. Viallard JF, Neau D, Monlun E, Longy-Boursier M, Le Bras M. Hypereosinophilia associated with heparin: A case with a challenge test. Therapie 1994; 49: 518.
26. Cines DB, Bussel JB, McMillan RB, Zehnder JL. Congenital and acquired thrombocytopenia. Hematology Am Soc Hematol Educ Program 2004; 390-406.
27. Handschin AE, Trentz O, Kock HJ, Wanner GA. Low molecular weight heparin-induced skin necrosis-a systematic review. Langenbecks Arch Surg 2005; 390: 249-54.
28. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: A critical review. Arch Intern Med 2004; 164: 361-9
29. Amiral J, Meyer D. Heparin-dependent antigens in heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, Eds. Heparin-induced thrombocytopenia. New York-Basel: Marcel Dekker, Inc. 2004; 165-77.
30. Warkentin TE. Heparin-induced thrombocytopenia: Diagnosis and management. Circulation 2004; 110: E454-8.
31. Chong BH, Magnani HN. Danaparoid for the treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, Eds. Heparin-induced thrombocytopenia. New York-Basel: Marcel Dekker, Inc. 2004.
32. Savi P, Chong BH, Greinacher A, Gruel Y, Kelton JG, Warkentin TE, et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: A blinded comparative multicenter study with unfractionated heparin. Blood 2005; 105: 139-44.
33. Greinacher A, Warkentin TE. Recognition, treatment, and prevention of heparin-induced thrombocytopenia: Review and update. Thromb Res 2006; 118: 165-76.
34. Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 2003; 108: 2062-5.
35. Bartholomew JR. Bivalirudin for the treatment of heparin induced thrombocytopenia. In Heparin-Induced Thrombocytopenia. New York - Basel Marcel-Decker Inc. 2004; 475-508.
36. Greinacher A, Eichler P, Albrecht D, Strobel U, Potzsch B, Eriksson BI. Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hipreplacement surgery: incidence and clinical relevance. Blood 2003; 101: 2617-9.
37. Eichler P, Lubenow N, Strobel U, Greinacher A. Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin. Blood 2004; 103: 613-6.
38. Bircher AJ, Czendlik C, Langauer Messmer S, Müller P, Howald H. Acute urticaria from subcutaneous recombinant hirudin. Evidence for an IgG-mediated hypersensitivity reaction. J Allergy Clin Immunol 1996; 98: 994-6.
39. Zollner TM, Gall H, Volpel H, Kaufmann R. Type IV allergy to natural hirudin confirmed by in vitro stimulation with recombinant hirudin. Contact Dermatitis 1996; 35: 59-60.
40. Smith KJ, Rosario-Collazo J, Skelton H. Delayed cutaneous hypersensitivity reactions to hirudin. Arch Pathol Lab Med 2001; 125: 1585-7.
41. Jappe U, Reinhold D, Bonnekoh B. Arthus reaction to lepirudin, a new recombinant hirudin, and delayed-type hypersensitivity to several heparins and heparinoids, with tolerance to its intravenous administration. Contact Dermatitis 2002; 46: 29-32.
42. Chan YC, Valenti D, Mansfield AO, Stansby G. Warfarin induced skin necrosis. Br J Surg 2000; 87: 266-72.
43. Essex DW, Wynn SS, Jin DK. Late-onset warfarin-induced skin necrosis: case report and review of the literature. Am J Hematol 1998; 57: 233-7.
44. Antony SJ, Krick SK, Mehta PM. Unusual cutaneous adverse reaction to warfarin therapy. South Med J 1993; 86: 1413-4.
45. Kruis-de Vries MH, Stricker BH, Coenraads PJ, Nater JP. Maculopapular rash due to coumarin derivatives. Dermatologica 1989; 178: 109-11.
46. Lebsack CS, Weibert RT. "Purple toes" syndrome. Postgrad Med 1982; 71: 81-4.
47. Talmadge DB, Spyropoulos AC. Purple toes syndrome associated with warfarin therapy in a patient with antiphospholipid syndrome. Pharmacotherapy 2003; 23: 674-7.
48. Spyropoulos AC, Hayth KA, Jenkins P. Anticoagulation with anis-indione in a patient with a warfarin-induced skin eruption. Pharmacotherapy 2003; 23: 533-6.
49. Sheps SG, Gifford RW Jr. Urticaria after administration of warfarin sodium. Am J Cardiol 1959; 3: 118-20.
50. Parslew R, Pryce D, Ashworth J, Friedmann PS. Warfarin treatment of chronic idiopathic urticaria and angio-oedema. Clin Exp Allergy 2000; 30: 1161-5.
51. Barlow RJ, Greaves MW. Warfarin in the treatment of chronic urticaria/ angio-edema. Br J Dermatol 1992; 126: 415-6.
52. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: The relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 234S-64S.
53. Pfaar O, Klimek L. Aspirin desensitization in aspirin intolerance: update on current standards and recent improvements. Curr Opin Allergy Clin Immunol 2006; 6: 161-6.
54. Berges-Gimeno MP, Martin-Lazaro J. Allergic reactions to non-steroidal anti-inflammatory drugs: Is newer better? Curr Allergy Asthma Rep 2007; 7: 35-40.
55. Schiavino D, Nucera E, Milani A, Del Ninno M, Buonomo A, Sun J, et al. The aspirin disease. Thorax 2000; 55(Suppl 2): S66-9.
56. de Weck AL, Gamboa PM, Esparza R, Sanz ML. Hypersensitivity to aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs). Curr Pharm Des 2006; 12: 3347-58.
57. Jenneck C, Juergens U, Buecheler M, Novak N. Pathogenesis, diagnosis, and treatment of aspirin intolerance. Ann Allergy Asthma Immunol 2007; 99: 13-21.
58. Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2002; 89: 474-8.
59. Pfaar O, Klimek L. Eicosanoids, aspirin-intolerance and the upper airways-current standards and recent improvements of the desensitization therapy. J Physiol Pharmacol 2006; 57(Suppl 12): 5-13.
60. Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 2004; 328: 434.
61. Kasper L, Sladek K, Duplaga M, Bochenek G, Liebhart J, Gladysz U, et al. Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland. Allergy 2003; 58: 1064-6.
62. Vally H, Taylor ML, Thompson PJ. The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients. Thorax 2002; 57: 569-74.
63. Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 2006; 118: 773-86; quiz 87-8.
64. Penrose JF, Baldasaro MH. Leukotriene C4 synthase: A candidate gene for the aspirin-intolerant asthmatic phenotype. Allergy Asthma Proc 1999; 20: 353-60.
65. Sousa AR, Parikh A, Scadding G, Corrigan CJ, Lee TH. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002; 347: 1493-9.
66. Picado C. Aspirin-intolerant asthma: Role of cyclo-oxygenase enzymes. Allergy 2002; 57(Suppl 72): 58-60.
67. Sanak M, Levy BD, Clish CB, Chiang N, Gronert K, Mastalerz L, et al. Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur Respir J 2000; 16: 44-9.
68. Kowalski ML, Ptasinska A, Bienkiewicz B, Pawliczak R, DuBuske L. Differential effects of aspirin and misoprostol on 15-hydroxyeicosatetraenoic acid generation by leukocytes from aspirin-sensitive asthmatic patients. J Allergy Clin Immunol 2003; 112: 505-12.
69. Kowalski ML, Ptasinska A, Jedrzejczak M, Bienkiewicz B, Cieslak M, Grzegorczyk J, et al. Aspirin-triggered 15-HETE generation in peripheral blood leukocytes is a specific and sensitive Aspirin-Sensitive Patients Identification Test (ASPITest). Allergy 2005; 60: 1139-45.
70. Kowalski ML, Borowiec M, Kurowski M, Pawliczak R. Alternative splicing of cyclooxygenase-1 gene: Altered expression in leucocytes from patients with bronchial asthma and association with aspirin-induced 15-HETE release. Allergy 2007; 62: 628-34.
71. Devouassoux G, Pachot A, Laforest L, Diasparra J, Freymond N, Van Ganse E, et al. Galectin-10 mRNA is overexpressed in peripheral blood of aspirin-induced asthma. Allergy 2008; 63: 125-31.
72. Sanz ML, Gamboa P, de Weck AL. A new combined test with flowcytometric basophil activation and determination of sulfidoleukotrienes is useful for in vitro diagnosis of hypersensitivity to aspirin and other nonsteroidal anti-inflammatory drugs. Int Arch Allergy Immunol 2005; 136: 58-72.
73. Pacor ML, Di Lorenzo G, Mansueto P, Martinelli N, Esposito-Pellitteri M, Pradella P, et al. Relationship between human leucocyte antigen class I and class II and chronic idiopathic urticaria associated with aspirin and/or NSAIDs hypersensitivity. Mediators Inflamm 2006; 2006: 62489.
74. Kim SH, Choi JH, Lee KW, Kim SH, Shin ES, Oh HB, et al. The human leucocyte antigen-DRB1*1302-DQB1*0609-DPB1*0201 haplotype may be a strong genetic marker for aspirin-induced urticaria. Clin Exp Allergy 2005; 35: 339-44.
75. Castells M. Desensitization for drug allergy. Curr Opin Allergy Clin Immunol 2006; 6: 476-81.
76. Silberman S, Neukirch-Stoop C, Steg PG. Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. Am J Cardiol 2005; 95: 509-10.
77. Page NA, Schroeder WS. Rapid desensitization protocols for patients with cardiovascular disease and aspirin hypersensitivity in an era of dual antiplatelet therapy. Ann Pharmacother 2007; 41: 61-7.
78. Wong JT, Nagy CS, Krinzman SJ, Maclean JA, Bloch KJ. Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema. J Allergy Clin Immunol 2000; 105: 997-1001.
79. Fischer TC, Worm M, Groneberg DA. Clopidogrel-associated angioedema. Am J Med 2003; 114: 77-8.
80. Phillips EJ, Knowles SR, Shear NH. Serum sickness-like reaction associated with clopidogrel. Br J Clin Pharmacol 2003; 56: 583.
81. Doogue MP, Begg EJ, Bridgman P. Clopidogrel hypersensitivity syndrome with rash, fever, and neutropenia. Mayo Clin Proc 2005; 80: 1368-70
82. Comert A, Akgun S, Civelek A, Kavala M, Sarigul S, Yildirim T, et al. Clopidogrel-induced hypersensitivity syndrome associated with febrile pancytopenia. Int J Dermatol 2005; 44: 882-4.
83. Sarrot-Reynauld F, Bouillet L, Bourrain JL. Severe hypersensitivity associated with clopidogrel. Ann Intern Med 2001; 135: 305-6.
84. Gutierrez-Fernandez D, Fuentes-Vallejo MS, Rueda-Ygueravides MD, Foncubierta-Fernandez A, Leon-Jimenez A. Immediate hypersensitivity and delayed hypersensitivity to clopidogrel. Allergol Immunopathol (Madr) 2007; 35: 213-5.
85. Owen P, Garner J, Hergott L, Page RL. Clopidogrel desensitization: Case report and review of published protocols. Pharmacotherapy 2008; 28: 259-70.
86. von Tiehl KF, Price MJ, Valencia R, Ludington KJ, Teirstein PS, Simon RA. Clopidogrel desensitization after drug-eluting stent placement. J Am Coll Cardiol 2007; 50: 2039-43.
87. Walker NE, Fasano MB, Hobbs RA, Horwitz PA. Clopidogrel desensitization protocol for the treatment of thienopyridine hypersensitivity. Crit Pathw Cardiol 2007; 6: 26-9.
88. Curtis BR, Divgi A, Garritty M, Aster RH. Delayed thrombocytopenia after treatment with abciximab: A distinct clinical entity associated with the immune response to the drug. J Thromb Haemost 2004; 2: 985-92.
89. Koch P. Delayed-type hypersensitivity skin reactions due to heparins and heparinoids. Tolerance of recombinant hirudins and of the new synthetic anticoagulant fondaparinux. Contact Dermatitis 2003; 49: 276-80.
90. Nicolie B, Bonneau JC, Le Sellin J, Gay G, Leclere JM, Drouet M. Delayed hypersensitivity to heparins and heparinoids. Allerg Immunol (Paris) 2002; 34: 47-50.
91. Grims RH, Weger W, Reiter H, Arbab E, Kranke B, Aberer W. Delayed-type hypersensitivity to low molecular weight heparins and heparinoids: cross-reactivity does not depend on molecular weight. Br J Dermatol 2007; 157: 514-7.
92. Wurpts G, Merk HF. Delayed intracutaneous test reaction in heparin intolerance. Hautarzt 2007; 58: 394-6.
93. Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: General considerations. Allergy 2003; 58: 854-63.
94. Quiralte J, Blanco C, Delgado J, Ortega N, Alcntara M, Castillo R, et al. Challenge-based clinical patterns of 223 Spanish patients with nonsteroidal anti-inflammatory-drug-induced-reactions. J Investig Allergol Clin Immunol 2007; 17: 182-8.
95. Bircher AJ. Diagnostic tests for delayed type-hypersensitivity reactions to heparins and safety of intravenous heparin. Am J Contact Dermatitis 1994; 5: 56-7.
96. Bircher AJ, Itin P, Tsakiris D, Surber C. Delayed hypersensitivity to one low-molecular-weight heparin with tolerance of other low-molecular-weight heparins. Br J Dermatol 1995; 132: 461-3.
97. Ji SL, Cui HF, Shi F, Chi YQ, Cao JC, Geng MY, et al. Inhibitory effect of heparin-derived oligosaccharides on secretion of interleukin-4 and interleukin-5 from human peripheral blood T lymphocytes. World J Gastroenterol 2004; 10: 3490-4.
98. Caballero MR, Fernandez-Benitez M. Allergy to heparin: A new in vitro diagnostic technique. Allergol Immunopathol (Madr) 2003; 31: 324-8.
99. Ebo DG, Haine SE, Hagendorens MM, Bridts CH, Conraads VM, Vorlat A, et al. Hypersensitivity to nadroparin calcium: Case report and review of the literature. Clin Drug Investig 2004; 24: 421-6.
100. Bircher AJ, Hédin H, Berglund A. Probable grade IV dextran-induced anaphylactic reaction despite hapten inhibition. J Allergy Clin Immunol 1995; 95: 633-4.
101. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 311S-37S.
102. Maetzke J, Hinrichs R, Schneider LA, Scharffetter-Kochanek K. Unexpected delayed-type hypersensitivity skin reactions to the ultra-low-molecular-weight heparin fondaparinux. Allergy 2005; 60: 413-5.
103. Maetzke J, Hinrichs R, Staib G, Scharffetter-Kochanek K. Fonda-parinux as a novel therapeutic alternative in a patient with heparin allergy. Allergy 2004; 59: 237-8.
104. Jappe U, Juschka U, Kuner N, Hausen BM, Krohn K. Fonda-parinux: A suitable alternative in cases of delayed-type allergy to heparins and semisynthetic heparinoids? A study of 7 cases. Contact Dermatitis 2004; 51: 67-72.
105. Maroto-Iitani M, Higaki Y, Kawashima M. Cutaneous allergic reaction to heparins: Subcutaneous but not intravenous provocation. Contact Dermatitis 2005; 52: 228-30.
106. Patriarca G, Rossi M, Schiavino D, Schinco G, Fais G, Varano C, et al. Rush desensitization in heparin hypersensitivity: A case report. Allergy 1994; 49: 292-4.
107. Barantke M, Bonnemeier H. Factor Xa inactivation in acute coronary syndrome. Curr Pharm Des 2008; 14(12): 1186-90.
108. Hartmann F. Safety and efficacy of bivalirudin in acute coronary syndromes. Curr Pharm Des 2008; 14(12): 1191-6.
109. Joost A, Kurowski V, Radke PW. Anticoagulation in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary angiography and interventions. Curr Pharm Des 2008; 14(12): 1176-85